Back

Evaluation of a fully automated Multiplexed Bead assay for assessment of Epstein-Barr virus immunologic status

Abstract number: 1733_666

Baccard M., Seigneurin J.M.

Detection of clinically relevant circulating Epstein-Barr virus (EBV) specific and heterophile antibodies in serum are essential for the diagnosis of EBV infection and determination of the patient EBV serology status. Currently, specific serological assays using either indirect immunofluorescence or enzyme-linked immunosorbent (ELISA) are performed to evaluate the status of Epstein-Barr virus (EBV) infection in humans. Even if reliable, these methods are limited to testing an antibody response to a single viral antigen per reaction, thus necessitating a panel of assays to complete the evaluation.

The aim of this study was to evaluate the performance of the BioPlex 2200 EBV IgG and IgM Panels (Bio-Rad Laboratories, Hercules, CA), a new fully automated multiplex method that can simultaneously detect in a single tube VCA, EBNA-1 and EA-D IgG and VCA IgM and heterophile antibodies.

610 serum samples from 508 patients including seronegative and positive clinically documented samples (119 Infectious Mononucleosis [IM] and other stages of the infection) were tested both with the BioPlex 2200 panels and the assays routinely used in the lab.

Specificity on negative samples was 98.2% and ranged from 96 to 100% on clinical samples depending on the analyte. The clinical sensitivity on acute and IM samples was up to 95% for VCA IgM and 96.4% for heterophile. Combining those two analytes improved the clinical sensitivity on those samples. For past infection samples, VCA IgG clinical sensitivity was 97%. Sensitivity on clinical samples for EBNA-1 and EA-D IgG was respectively 98 and 87%. Concordance calculation demonstrated overall agreement of 90% for VCA IgM, 93% for heterophile antibody and 77% for VCA IgG (especially due to difference in the antibodies kinetic during primary infection). The correlation between samples classification based on BioPlex 2200 results and status determined with the lab routine assays was of 83% including atypical profiles and immunocompromised patients.

Conclusion: the BioPlex 2200 EBV IgG and IgM Panels showed very good interpretation concordance with the routine lab assays. Furthermore, the BioPlex 2200, the first and only fully-automated, random access multiplex EBV testing platform offers practical advantages that allow for rapid and simultaneous evaluation of the five most clinically relevant antibodies including heterophile for accurate assessment of EBV Immunologic Status.

Session Details

Date: 31/03/2007
Time: 00:00-00:00
Session name: European Society of Clinical Microbiology and Infectious Diseases
Subject:
Location: ICC, Munich, Germany
Presentation type:
Back to top